Skip to main content
Year archive

Nanobiotix — 2025 filings

All 85 regulatory filings released by Nanobiotix (NANO) in 2025, sourced directly from the official regulator.

85 Filings
2025 Period
2025 filings (85)
Filing Released Lang
Franchissement de seuils
Major Shareholding Notification
2025-12-15 French
Franchissement de seuils
Major Shareholding Notification
2025-12-15 French
NANOBIOTIX va intégrer les indices CAC Mid 60 et SBF 120 d’Euronext Paris
Regulatory Filings
2025-12-15 French
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
Regulatory Filings
2025-12-15 English
Franchissement de seuils
Major Shareholding Notification
2025-12-05 French
Franchissement de seuil
Major Shareholding Notification
2025-11-28 French
Franchissement de seuil
Major Shareholding Notification
2025-11-17 French
Franchissements de seuil
Major Shareholding Notification
2025-11-17 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2025-11-14 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2025-11-14 French
NANOBIOTIX annonce les avancées de sa plateforme de nanoprimer Curadigm avec une mise à jour des plans de développement pour son pipeline interne et des collaborations externes
Regulatory Filings
2025-11-13 French
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
Regulatory Filings
2025-11-13 English
Franchissement de seuil
Major Shareholding Notification
2025-11-13 French
Franchissement de seuil
Regulatory Filings
2025-11-13 French
Franchissement de seuil
Regulatory Filings
2025-11-13 French
NANOBIOTIX participera à la conférence Jefferies London Healthcare
Regulatory Filings
2025-11-11 French
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
Regulatory Filings
2025-11-11 English
Franchissement de seuils
Major Shareholding Notification
2025-11-04 French
NANOBIOTIX annonce un accord stratégique avec HealthCare Royalty pour un montant maximum de 71 millions de dollars et prolonge ainsi son horizon de trésorerie pour une croissance durable
Capital/Financing Update
2025-10-31 French
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Capital/Financing Update
2025-10-31 English
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
Regulatory Filings
2025-10-24 English
NANOBIOTIX annonce des mises à jour sur le programme clinique de JNJ-1900 (NBTXR3) à la suite du transfert de sponsorship et du contrôle opérationnel de l’essai de Phase 3 en cours dans le cancer de l
Regulatory Filings
2025-10-24 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2025-10-15 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2025-10-15 French
NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage
Regulatory Filings
2025-10-01 French
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Earnings Release Q4 2025
2025-10-01 English
RAPPORT FINANCIER SEMESTRIEL
Interim / Quarterly Report H1 2025
2025-09-30 French
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Earnings Release H1 2025
2025-09-30 English
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025
Earnings Release H1 2025
2025-09-30 French
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Regulatory Filings
2025-09-30 English
Franchissements de seuils
Major Shareholding Notification
2025-09-19 French
NANOBIOTIX annonce de nouveaux résultats de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle en traitement de deuxième ligne ou plus chez des patients attei
Regulatory Filings
2025-09-17 French
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resist
Regulatory Filings
2025-09-17 English
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements
2025-09-12 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2025-09-12 English
Franchissement de seuils
Major Shareholding Notification
2025-09-09 French
Franchissement de seuils
Major Shareholding Notification
2025-09-08 French
Nanobiotix participera à la conférence investisseurs annuelle H.C. Wainwright global investment
Regulatory Filings
2025-09-02 French
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Regulatory Filings
2025-09-02 English
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2025-08-27 English
Franchissements de seuils
Major Shareholding Notification
2025-08-11 French
Franchissements de seuils
Major Shareholding Notification
2025-08-11 French
Franchissement de seuils
Major Shareholding Notification
2025-07-11 French
Franchissement de seuils
Major Shareholding Notification
2025-07-11 French
NANOBIOTIX annonce une harmonisation réglementaire et le dépôt d’une demande d’un nouveau brevet de composition de matière pour JNJ-1900 (NBTXR3)
Investor Presentation
2025-07-07 French
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
Regulatory Filings
2025-07-07 English
Franchissement de seuils
Major Shareholding Notification
2025-07-01 French
Franchissement de seuils
Major Shareholding Notification
2025-06-24 French
Franchissement de seuils
Major Shareholding Notification
2025-06-20 French
Franchissement de seuils
Major Shareholding Notification
2025-06-20 French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2025-06-10 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2025-06-10 English
NANOBIOTIX participera à la conférence investisseurs annuelle Jefferies Global Healthcare
Regulatory Filings
2025-05-28 French
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
Regulatory Filings
2025-05-28 English
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
Earnings Release Q1 2025
2025-05-21 English
Nanobiotix fait le point sur sa trésorerie et son activité opérationnelle du premier trimestre 2025
Earnings Release Q1 2025
2025-05-21 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements
2025-05-14 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2025-05-14 English
Nanobiotix participera à la 3ème conférence investisseurs annuelle H.C. Wainwright BioConnect au NASDAQ
Regulatory Filings
2025-05-12 French
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Regulatory Filings
2025-05-12 English
NANOBIOTIX PRÉSENTE LES RÉSULTATS COMPLETS DE L’ÉTUDE DE PHASE 1 ÉVALUANT JNJ-1900 (NBTXR3) DANS LE CANCER DU PANCREAS
Regulatory Filings
2025-05-05 French
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
Earnings Release Q2 2025
2025-05-05 English
Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast
Earnings Release Q2 2025
2025-04-30 French
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
Regulatory Filings
2025-04-30 English
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements
2025-04-14 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2025-04-14 English
Document d'Enregistrement Universel
Annual Report (ESEF) FY 2024
2025-04-02 French
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2024
Report Publication Announcement FY 2024
2025-04-02 French
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
Earnings Release FY 2024
2025-04-02 English
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
Report Publication Announcement
2025-03-31 English
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2024 le 2 avril 2025
Report Publication Announcement
2025-03-31 French
Nanobiotix annonce les premières données issues de la partie escalade de dose completée d’une étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d’un CPNPC loc
Earnings Release Q1 2025
2025-03-27 French
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Earnings Release Q1 2025
2025-03-27 English
NANOBIOTIX annonce la présentation de données issues de deux études de phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer du Poumon
Regulatory Filings
2025-03-20 French
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Regulatory Filings
2025-03-20 English
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
M&A Activity
2025-03-17 English
NANOBIOTIX renforce sa visibilité financière en amendant son accord de licence globale pour JNJ-1900 (NBTXR3) qui étend son horizon de trésorerie jusqu’à mi-2026
Earnings Release Q1 2025
2025-03-17 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2025-03-13 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2025-03-13 French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2025-02-12 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2025-02-12 English
NANOBIOTIX annonce le traitement du premier patient dans une nouvelle étude randomisée de phase 2 évaluant JNJ-1900 (NBTXR3) chez des patients atteints d’un cancer du poumon non à petites cellules de
Regulatory Filings
2025-01-21 French
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
Regulatory Filings
2025-01-21 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2025-01-09 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements
2025-01-09 English